A share price of Avidity Biosciences Inc [RNA] is currently trading at $32.93, up 0.92%. An important factor to consider is whether the stock is rising or falling in short-term value. The RNA shares have gain 10.99% over the last week, with a monthly amount glided 12.85%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on December 20, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $72. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on November 26, 2024, and set its price target to $67. On September 24, 2024, Goldman initiated with a Buy rating and assigned a price target of $59 on the stock. Barclays started tracking the stock assigning a Overweight rating and suggested a price target of $63 on August 28, 2024. BofA Securities initiated its recommendation with a Buy and recommended $40 as its price target on May 03, 2024. Cantor Fitzgerald started tracking with a Overweight rating for this stock on March 14, 2024, and assigned it a price target of $60. In a note dated May 22, 2023, Evercore ISI upgraded an Outperform rating on this stock but restated the target price of $20.
Avidity Biosciences Inc experienced fluctuations in its stock price throughout the past year between $11.23 and $56.00. Currently, Wall Street analysts expect the stock to reach $59 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $32.93 at the most recent close of the market. An investor can expect a potential return of 79.17% based on the average RNA price forecast.
Analyzing the RNA fundamentals
Trailing Twelve Months sales for Avidity Biosciences Inc [NASDAQ:RNA] were 10.12M which represents -17.10% decline. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -32.09%, Pretax Profit Margin comes in at -27.72%, and Net Profit Margin reading is -27.72%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.28 and Total Capital is -0.21. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 32.28 points at the first support level, and at 31.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 33.73, and for the 2nd resistance point, it is at 34.53.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Avidity Biosciences Inc [NASDAQ:RNA] is 17.76. On the other hand, the Quick Ratio is 17.76, and the Cash Ratio is 4.05. Considering the valuation of this stock, the price to sales ratio is 388.23, the price to book ratio is 2.60.
Transactions by insiders
Recent insider trading involved LEVIN ARTHUR A, Director, that happened on Jan 21 ’25 when 1872.0 shares were sold. Chief Financial Officer, MacLean Michael F completed a deal on Jan 21 ’25 to sell 3287.0 shares. Meanwhile, Chief Human Resources Officer McCarthy Teresa sold 2959.0 shares on Jan 21 ’25.
